Bifogade filer
Kurs
-1,50%
Likviditet
0,42 MNOK
Kalender
Est. tid* | ||
2025-08-28 | 18:50 | Kvartalsrapport 2025-Q2 |
2025-06-06 | N/A | X-dag ordinarie utdelning CRNA 0.00 NOK |
2025-06-05 | N/A | Årsstämma |
2025-04-10 | - | Bokslutskommuniké 2024 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-06-19 | - | Årsstämma |
2024-06-06 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2024-04-25 | - | Bokslutskommuniké 2023 |
2023-10-04 | - | Split CRNA 30:1 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-22 | - | Årsstämma |
2023-04-21 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2023-03-09 | - | Extra Bolagsstämma 2023 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-04-20 | - | Årsstämma |
2022-04-07 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-25 | - | Extra Bolagsstämma 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-08-18 | - | Kvartalsrapport 2021-Q2 |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-03-18 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2021-03-17 | - | Årsstämma |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-04-30 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2020-04-29 | - | Årsstämma |
2020-03-11 | - | Bokslutskommuniké 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-09 | - | Kvartalsrapport 2019-Q1 |
2019-04-10 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2019-04-09 | - | Årsstämma |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-01 | - | Kvartalsrapport 2018-Q3 |
2018-08-23 | - | Kvartalsrapport 2018-Q2 |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-04-12 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2018-04-11 | - | Årsstämma |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-11-16 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-04-25 | - | Kvartalsrapport 2017-Q1 |
2017-04-05 | - | Årsstämma |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-11-17 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-12 | - | Kvartalsrapport 2016-Q1 |
2016-04-14 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2016-04-13 | - | Årsstämma |
2015-06-23 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2015-06-22 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | Oslo Bors |
Sektor | Hälsovård |
Industri | Bioteknik |
Oslo, 15 May 2025: The annual general meeting of Circio Holding ASA (the "Company") will be held on Thursday 5 June 2025 at 10:00 hours (CEST) as a physical meeting at the Company's offices at Universitetsgata 2, 0164 Oslo.
The notice and agenda of the annual general meeting is attached hereto, including further information on advance voting, power of attorney and physical participation. The notice and the nomination committees recommendation, and the documents referred to therein are made available on the Company's webpage www.circio.com under the heading "Investors".
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS -mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.